Loading...
Sutro Biopharma Community
NasdaqGM:STRO Community- 2 Narratives written by author
- 0 Comments on narratives written by author
- 9 Fair Values set on narratives written by author
Community Investing Ideas
Cell-Free Platform Will Unlock Broad Personalized Oncology Opportunities
Key Takeaways Strategic focus on advanced ADC programs and external manufacturing partnerships positions Sutro for accelerated revenue growth, high margins, and reduced dilution risk. Proprietary cell-free platform and pipeline strength enable leadership in personalized oncology, supporting premium pricing, diverse partnerships, and substantial expansion opportunities.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$5
81.9% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue growth
1.02% p.a.
Profit Margin
10.07%
Future PE
52.03x
Share price in 2028
US$6.13
ADC Pipeline Focus Will Advance Preclinical Drug Development
Key Takeaways Strategic focus on preclinical programs and restructuring is set to drive future growth by enhancing drug development and revenue potential. Workforce reduction and externalization aim to improve margins and extend the cash runway, while partnerships and out-licensing bolster financial flexibility.Read more
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
US$2.69
66.3% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
-21.56% p.a.
Profit Margin
14.17%
Future PE
42.45x
Share price in 2028
US$3.29